An engineered human renal tubular epithelial cell line and its application

By constructing the HK2-OAT1-OAT3-OCT2 cell line through gene editing and combining it with a highly biocompatible membrane, the problems of insufficient toxin removal capacity and poor material compatibility of seed cells in bioartificial kidney devices were solved, achieving efficient removal of medium and large molecular uremic toxins and retention of nutrients.

CN123063341APending Publication Date: 2026-11-10SHANDONG UNIV QILU HOSPITAL
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202611592630.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-15
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

In existing bioartificial kidney devices, the seed cells have insufficient toxin removal capacity, improper material selection leads to poor filtration of macromolecular substances, and the cells are prone to detachment. They cannot effectively remove medium and large molecular uremic toxins and nutrients, and cannot replace the metabolic and endocrine functions of the kidney.

Method used

The HK2-OAT1-OAT3-OCT2 cell line was constructed using gene editing techniques. OAT1, OAT3, and OCT2 transport proteins were stably overexpressed and combined with a highly biocompatible cell support membrane to construct a bioartificial kidney device. This device achieves tight cell-membrane binding, forming a dense monolayer that mimics the active uptake function of the proximal tubules of the human kidney.

Benefits of technology

It significantly improves the clearance capacity of medium and large molecular uremic toxins, enhances the retention of nutrients, solves the problem of easy cell detachment, and achieves highly efficient clearance of uremic toxins and retention of nutrients in bioartificial kidneys.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123063341A_ABST
    Figure CN123063341A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of biological engineering and regenerative medicine, specifically relating to an engineered human renal tubular epithelial cell line and its applications. The engineered HK2-OAT1-OAT3-OCT2 cell line provided by this invention stably overexpresses OAT1, OAT3, and OCT2. After culturing on a PET membrane for 7 days, it forms a dense monolayer with polarized transport proteins, enabling it to actively take up, transport, and secrete uremic toxins. In vitro and in vivo experiments show that the bioartificial kidney device prepared by combining this cell line with a PET membrane can effectively remove creatinine, urea nitrogen, and protein-bound uremic toxins, exhibiting good biocompatibility. This invention provides a safe and efficient new renal replacement therapy for patients with end-stage renal failure.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biological engineering and regenerative medicine technology, and specifically relates to an engineered human renal tubular epithelial cell line (named: HK2-OAT1-OAT3-OCT2) and its applications, particularly the application of this cell line and its cellularized biomembrane composed of a specific cell support membrane in the preparation of bioartificial kidney devices for treating end-stage renal failure or clearing uremic toxins and other related products. Background Technology

[0002] End-stage renal failure (ESRD) is the final stage of many chronic kidney diseases, characterized by chronic, progressive, and irreversible destruction of nephrons. This leads to the inability to eliminate metabolic waste and toxins, ultimately causing multi-organ system disease. Kidney transplantation is currently the most effective treatment, but it faces challenges such as high surgical costs, the need for long-term immunosuppressants for patients, and a severe shortage of transplantable kidneys.

[0003] Hemodialysis is currently the most widely used treatment for ESRD in clinical practice. However, traditional dialysis can only filter out small molecule toxins, lacking the core physiological functions of reabsorption, endocrine, and metabolism in the proximal renal tubules of the human kidney. It cannot remove medium and large molecule uremic toxins (such as β2-microglobulin) or protein-bound uremic toxins (PBUTs) (such as indophenol sulfate and p-cresol sulfate). Furthermore, long-term dialysis can lead to renal osteodystrophy, dialysis amyloidosis, and cardiovascular complications, as well as complications such as infection, metabolic disorders, and anemia. In addition, hemodialysis can only provide partial filtration in a non-physiological, intermittent manner and cannot replace the metabolic and endocrine functions of the kidneys.

[0004] Bioartificial kidney (BAK) is a promising kidney replacement therapy developed through cell therapy and bioengineering technology. Unlike traditional hemodialysis, which mainly relies on physical clearance mechanisms such as diffusion, convection, and sieving through semipermeable membranes, BAK couples functional renal tubular epithelial cells with complete physiological activity to the blood filtration membrane. It can fully simulate multiple physiological functions of the human proximal renal tubules, such as active transport, specific reabsorption, toxin metabolism and degradation, and endocrine regulation. It can make up for the shortcomings of conventional hemodialysis, such as the inability to remove medium and large molecular uremic toxins, loss of essential nutrients, and lack of renal endocrine activity. It is the core technology route for replacing traditional dialysis in the future.

[0005] At present, the seed cell selection schemes for bioartificial kidneys are mainly divided into: primary human proximal renal tubular epithelial cells, unmodified immortalized renal tubular cell lines, renal tubular epithelial-like cells obtained by directed differentiation of pluripotent stem cells, and renal tubular organoids or Tubuloid-derived cells, such as patents CN12055363A and CN120866232A, which disclose the technical solution of isolating primary renal tubular epithelial cells from human renal cortex tissue, constructing cell lines through immortalization modification, and applying them to bioartificial kidneys. While this approach can obtain human renal tubular epithelial cells, it suffers from several drawbacks. First, primary cell sourcing relies on human donor kidneys, which are scarce or subject to ethical restrictions. Furthermore, the cells undergo extremely low passage numbers in vitro, showing significant dedifferentiation within five consecutive passages, failing to meet the industrialization requirements for large-scale expansion and long-term dynamic perfusion culture of bioartificial kidneys. Second, even after immortalization, the expression levels of natural transport proteins in primary-derived cell lines without targeted gene modification are limited, resulting in weak uptake, transport, and clearance of protein-bound, medium- to large-molecule uremic toxins such as indophenol sulfate, p-cresol sulfate, hippuric acid, and β2-microglobulin. Consequently, their toxin clearance and nutrient retention effects in bioartificial kidneys do not meet clinical treatment expectations. In addition, issues such as material selection, cell culture conditions, and immune isolation in bioartificial kidney devices have not yet been systematically resolved.

[0006] HK2 cells are currently the most widely used standardized human proximal tubular epithelial cell line in the field of renal tubular function and nephrotoxicity research worldwide. Constructed by Ryan's team in 1994, the cells are derived from the proximal tubular tissue of healthy human renal cortex. Stable immortalization is achieved through the integration of HPV16 E6 / E7 oncogenes mediated by recombinant retroviruses. They can be passaged continuously indefinitely, have stable batch characteristics, and can be expanded on a large scale at a low cost. The basic phenotype can express renal tubular characteristic markers such as cytokeratin and alkaline phosphatase. They naturally possess certain glucose reabsorption and small molecule transport capabilities, making them the preferred seed cells for constructing bioartificial renal tubular reactors.

[0007] However, after long-term in vitro dynamic perfusion culture, the promoters of the organic anion transporters OAT1 / OAT3 in naturally unmodified HK2 cells undergo persistent methylation and epigenetic silencing. The expression levels of OAT1 / OAT3 and OCT2 transporters are significantly downregulated or even almost absent. After the loss of transporters, naturally unmodified HK2 cells lose their ability to transmembrane transport of medium and large molecular weight uremic toxins, which pose the greatest clinical threat. They can only achieve passive diffusion of small molecules of creatinine and urea, which cannot solve the clinical technical problems of high incidence of dialysis amyloidosis, renal osteodystrophy, and cardiovascular complications in long-term dialysis patients.

[0008] In addition, most cell support membranes at present are made of materials such as polyacrylonitrile and polyamide, but these materials are not very effective at filtering large molecules in the blood, and the tightness of the connection between different cell support membranes and cells varies significantly depending on the cell line.

[0009] If we can use gene editing to selectively modify HK2 cells, addressing the inherent weakness of insufficient toxin removal capacity in natural HK2 cell lines at the cellular level, and then combine this with a highly biocompatible cell support membrane to construct an integrated bioartificial kidney device, we can simultaneously achieve multiple effects such as efficient uremic toxin removal and nutrient retention.

[0010] Therefore, developing a multi-target gene-modified HK2 cell line to construct a bioartificial kidney device with both high-efficiency toxin removal capacity and excellent biocompatibility, and overcoming the technical bottlenecks of existing seed cell transport function defects, poor reactor material adaptability, and easy cell damage and shedding, has important clinical therapeutic value and market prospects. Summary of the Invention

[0011] To address the above technical problems, this invention proposes an engineered human renal tubular epithelial cell line and its applications, particularly the application of this cell line and the cellularized biomembrane formed by it combined with a specific cell support membrane in the preparation of bioartificial kidney devices for treating end-stage renal failure or clearing uremic toxins and other related products.

[0012] The technical solution provided by this invention is as follows:

[0013] The first aspect of this invention is to provide an engineered human renal tubular epithelial cell line, named HK2-OAT1-OAT3-OCT2. This cell line was deposited on September 1, 2026, at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, with accession number CGMCC No. 46875. The cell line is a human renal tubular epithelial cell line HK2 that overexpresses organic anion transporters OAT1 and OAT3, and organic cation transporter OCT2. This cell line is constructed using a PiggyBac vector carrying a TET-On gene expression regulation system and can stably overexpress OAT1, OAT3, and OCT2 transporters after doxycycline induction.

[0014] Preferably, the present invention also provides a method for constructing the HK2-OAT1-OAT3-OCT2 cell line, comprising the following steps:

[0015] Acquisition and artificial synthesis of the S1 target gene sequence

[0016] The gene sequences of human OAT1, OAT3, and OCT2 were obtained from the NCBI gene database, and the target genes of OAT1, OAT3, and OCT2 were artificially synthesized.

[0017] Construction of S2 recombinant expression vector

[0018] The target genes OAT1, OAT3, and OCT2 synthesized in S1 were cloned into the PiggyBac vector carrying the TET-On inducible gene expression regulation system and GFP fluorescent label, and a recombinant PiggyBac plasmid carrying the OAT1, OAT3, and OCT2 genes was constructed. The nucleotide sequence is shown in SEQ ID NO:1.

[0019] S3 plasmid transfection

[0020] The recombinant PiggyBac plasmid of S2 was transfected into the human renal tubular epithelial cell line HK2 to obtain the human renal tubular epithelial cell line HK2-OAT1-OAT3-OCT2 that stably overexpresses OAT1, OAT3, and OCT2.

[0021] Preferably, in S3, the selection medium is replaced 48 h after transfection. The selection medium is RPMI1640 complete medium supplemented with 1 μg / mL puromycin and 2 μg / mL doxycycline, and the selection culture is continued for 2 to 3 weeks.

[0022] A second aspect of the present invention is to provide a cellular biomembrane comprising the above-described engineered human renal tubular epithelial cell line and a cell support membrane, wherein the engineered human renal tubular epithelial cell line is seeded onto the cell support membrane; the cell support membrane is selected from any one of polyethylene terephthalate (PET) membrane, polyethersulfone (PES-50) membrane, silica nanoporous membrane, polyethersulfone / polyvinylpyrrolidone (PES / PVP) composite membrane, and polysulfone (PSF) membrane.

[0023] Preferably, the cell support membrane is a PET membrane.

[0024] Preferably, the cell-side surface of the cell support membrane is provided with a cell carrier layer, wherein the cell carrier layer is selected from at least one of the following:

[0025] A surface-modified layer, which is formed by at least one of plasma treatment, collagen coating, laminin modification, or fibronectin modification.

[0026] A hydrogel layer, wherein the material of the hydrogel layer is selected from at least one of gelatin, alginate, Matrigel matrix gum or collagen;

[0027] The nanofiber scaffold layer is prepared by electrospinning, and its material is selected from at least one of polycaprolactone, polylactic acid-glycolic acid copolymer or gelatin.

[0028] Preferably, when a cell carrier layer is disposed on the cell-side surface of the cell support membrane, the cell support membrane is a PSF membrane.

[0029] Preferably, the non-cellular side surface of the cell support membrane is further provided with at least one layer of porous alumina immune isolation membrane to serve as an immune isolation agent.

[0030] Because porous alumina immunoassay membranes are thin and brittle, in practice, any one of porous titanium, 316L stainless steel, or PEEK scaffolds can be used to provide mechanical support for the porous alumina immunoassay membranes.

[0031] Preferably, the porous alumina has a pore size of 10 nm.

[0032] The cellular biomembrane provided by this invention involves culturing engineered human renal tubular epithelial cell lines on a cell support membrane for approximately 7 days. The cells then densely colonize the cell support membrane, forming a stable cellular biomembrane that tightly adheres to it, enabling the transport of various components. However, in practice, the tightness of cell adhesion varies depending on the material of the cell support membrane. For example, PET cell support membranes exhibit excellent cell adhesion in practical applications, thus eliminating the need for an additional cell carrier layer. Conversely, some membranes, such as PSF membranes, show poor cell adhesion during cell culture, requiring the use of a specific cell carrier layer. In this invention, L-Dopa combined with human IV collagen was used for seeding cells, resulting in better cell adhesion.

[0033] In this invention, in order to further improve the efficacy of the bioartificial kidney device, an immune isolation membrane can be set on the non-cellular side of the original cellular biomembrane to achieve a good immune isolation effect. Preferably, the immune isolation membrane can be made of porous alumina membrane. Since it is thin and brittle, in order to better support the immune isolation membrane to play its role, porous titanium, 316L stainless steel or PEEK scaffold with good biocompatibility can be selected to provide a certain degree of mechanical support for the immune isolation membrane.

[0034] A third aspect of the present invention is the application of the HK2-OAT1-OAT3-OCT2 cell line in the preparation of cell models for drug development and cell models for nephrotoxicity testing, as well as the application of the cell line or cellularized biomembrane in the preparation of products for treating end-stage renal failure or clearing uremic toxins, wherein the products are preferably bioartificial kidney devices.

[0035] The HK2-OAT1-OAT3-OCT2 cell line obtained by engineering the HK2 cell line can simultaneously overexpress three key uptake transport proteins, OAT1, OAT3, and OCT2, in HK2 cells. It can form a dense monolayer after 7 days of culture on the cell support membrane, which not only helps to restore the active uptake function of the proximal tubules of the kidney, but also effectively removes protein-bound uremic toxins, overcoming the deficiency of conventional hemodialysis in removing medium and large molecular toxins.

[0036] A fourth aspect of the present invention is to provide a bioartificial kidney device through which the function of the HK2-OAT1-OAT3-OCT2 cell line can be realized. Specifically, the bioartificial kidney device comprises:

[0037] A shell with an anticoagulant coating on its inner surface, the shell having at least one blood channel and at least two dialysate channels, the blood channel being located in the middle and the dialysate channels on both sides, wherein the anticoagulant coating is selected from any one of heparin coating, phosphorylcholine coating or albumin coating;

[0038] The cell support membrane is placed between the blood channel and the dialysate channel. The HK2-OAT1-OAT3-OCT2 cell line is seeded on the cell support membrane to form a cell-based biomembrane. The cell support membrane is preferably made of polyethylene terephthalate (PET).

[0039] The sealing and spacer structure used to seal the connection between the blood channel and the dialysate channel is preferably a gasket made of silicone, thermoplastic elastomer or polytetrafluoroethylene.

[0040] In the bioartificial kidney device provided by this invention, the material of the cell support membrane used for seeding cells is crucial. In the initial screening experiments, the inventors tried PSF membranes and polyethersulfone (PES) membranes of models UE010 and UE020. While the PSF membrane, as a cell support membrane, did not exhibit good cell adhesion during cell culture, adding a surface carrier layer could achieve good cell adhesion. The PES models UE010 and UE020 were too rigid, failing to adhere smoothly to the bottom of the culture plate and often exhibiting arching. Furthermore, the membrane's white and opaque nature hindered observation, and its cell adhesion was unsatisfactory. For these reasons, neither of the two PES membranes was ultimately adopted.

[0041] The present invention has the following advantages and effects compared with the prior art:

[0042] (1) The present invention constructs an engineered cell line that stably overexpresses OAT1, OAT3 and OCT2 transport proteins. This cell line can form a dense monolayer on the cell support membrane. The transport proteins are distributed in a polar manner facing the blood side, which can simulate the active uptake function of the proximal tubule of the human kidney and provide a preferred seed cell line for bioartificial kidney devices.

[0043] In vivo experimental results of treatment with the bioartificial kidney device showed that, compared with the HK2 and HK2-NC cell groups, the HK2-OAT1-OAT3-OCT2 cell group showed a more significant decrease in serum creatinine and blood urea nitrogen levels, demonstrating superior creatinine transport efficiency. In addition, in the in vitro clearance experiment of uremic toxins, the HK2-OAT1-OAT3-OCT2 cells also significantly reduced the levels of six uremic toxins, with clearance efficiency far superior to that of HK2 and HK2-NC cells.

[0044] (2) The bioartificial kidney provided by the present invention uses PET or PSF as the membrane material of the cell support membrane and selectively sets a cell carrier layer on the surface of the support membrane, which significantly improves the adhesion, proliferation and polarity establishment of engineered renal tubular epithelial cells. At the same time, a notch structure can be set on the cell support membrane to provide physical protection for the cells, enabling them to resist fluid shear stress, maintain the barrier function and transport activity of the dense monolayer, and solve the technical problems of easy cell detachment and difficulty in forming a functional monolayer in existing devices. Attached Figure Description

[0045] Figure 1 The image shows the results of mRNA and protein level detection of OAT1, OAT3, and OCT2 in HK2-OAT1-OAT3-OCT2 cells in Example 1 of this invention.

[0046] Figure 2 This diagram illustrates the polar distribution and barrier function of transport proteins OAT1, OAT3, and OCT2 after HK2-NC and HK2-OAT1-OAT3-OCT2 cells form a dense monolayer on a PET membrane in Example 2 of this invention.

[0047] Figure 3 This is a diagram showing the results of functional verification of OAT1 / OAT3 and OCT2 transporter proteins in HK2-NC cells and HK2-OAT1-OAT3-OCT2 cells in Example 3 of the present invention.

[0048] Figure 4 This is a schematic diagram of the actual bioartificial kidney, its disassembled parts, and its connection relationships in use, as provided in Embodiment 4 of the present invention.

[0049] Among them, 1-shell, 10-blood channel, 11-dialysis fluid channel, 101-blood channel inlet one, 102-blood channel outlet one, 111-dialysis fluid channel inlet two, 112-dialysis fluid channel outlet two, 2-cell support membrane, 3-sealing and spacer structure;

[0050] Figure 5 The diagram shows the clearance effects of different cell groups of bioartificial kidneys on rat creatinine and urea nitrogen in Example 4 of the present invention.

[0051] Figure 6 This is a diagram showing the in vitro clearance effect of different cell groups of bioartificial kidneys on uremic toxins in Example 4 of the present invention. Detailed Implementation

[0052] To enable those skilled in the art to better understand the present invention, the present invention will now be further described in conjunction with specific embodiments.

[0053] Example 1

[0054] The construction steps of an engineered human renal tubular epithelial cell line HK2-OAT1-OAT3-OCT2 are as follows:

[0055] Acquisition and artificial synthesis of the S1 target gene sequence

[0056] The gene sequences of human OAT1 (SLC22A6), OAT3 (SLC22A8), and OCT2 (SLC22A2) were obtained from the NCBI gene database, and the target genes of OAT1, OAT3, and OCT2 were synthesized by Sangon Biotech Co., Ltd.

[0057] Construction of S2 recombinant expression vector

[0058] The target genes OAT1, OAT3, and OCT2 synthesized in S1 were cloned into the PiggyBac vector containing a tetracycline-induced expression system (i.e., the TET-On gene expression regulation system) and a green fluorescent protein (GFP) label, respectively, to obtain recombinant PiggyBac plasmids carrying the OAT1, OAT3, and OCT2 genes, with nucleotide sequences as shown in SEQ ID NO:1.

[0059] S3 transfected the recombinant PiggyBac plasmid from S2 into human renal cortical proximal tubular epithelial cells (HK2 cells) (purchased from ATCC) using liposome transfection. Forty-eight hours after transfection, stable selection was performed using RPMI 1640 complete medium containing puromycin (1 μg / mL) and doxycycline (Dox, 2 μg / mL). After 2-3 weeks of selection, the engineered human renal tubular epithelial cell line HK2-OAT1-OAT3-OCT2, stably overexpressing OAT1, OAT3, and OCT2, was obtained. This line was deposited on September 1, 2026, at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, with accession number CGMCC No. 46875. An engineered control cell line uninduced by Dox (named HK2-NC) was used as a control, meaning no Dox was added and the three transport proteins were not expressed.

[0060] In this embodiment, Western blotting and quantitative reverse transcription polymerase chain reaction (qRT-PCR) were used to verify the expression of three transporters in this cell line. The results are as follows: Figure 1 As shown in the figure; A and B represent the fluorescence expression of GFP in HK2-NC and HK2-OAT1-OAT3-OCT2 cells, respectively; C represents the protein expression in HK2-NC and HK2-OAT1-OAT3-OCT2 cells; and D represents the mRNA expression in HK2-NC and HK2-OAT1-OAT3-OCT2 cells.

[0061] Figure 1 The results showed that HK2-NC cells did not express GFP fluorescence, while HK2-OAT1-OAT3-OCT2 cells expressed GFP fluorescence, demonstrating that doxycycline induced the overexpression of OAT1, OAT3, and OCT2 transporters. Compared with HK2-NC cells, the protein expression and mRNA expression levels of OAT1, OAT3, and OCT2 in HK2-OAT1-OAT3-OCT2 cells were significantly increased (P<0.001).

[0062] Example 2

[0063] Verification of transporter polarity expression and barrier function of the engineered human renal tubular epithelial cell line HK2-OAT1-OAT3-OCT2 constructed in Example 1 in a planar model.

[0064] Transwell chambers (0.4 μm pore size, PET material, Corning) were sterilized by UV irradiation for 30 min. The engineered HK2-OAT1-OAT3-OCT2 cells obtained in Example 1 were cultured at 3 × 10⁻⁶ cells / mL. 3The cells were seeded at a density of / wells onto a PET membrane and cultured in RPMI 1640 complete medium (Dox 2 μg / mL) for 7 days, with the medium changed daily. The following assays were performed on day 7:

[0065] (1) Immunofluorescence staining of OAT1, OAT3, and OCT2: Discard the culture medium, wash twice with PBS, add 200 μL of 4% paraformaldehyde fixative, fix for 10 min, wash three times with PBS for 5 min each time. The chamber membrane was gently separated with a scalpel, permeated with 0.1% Triton X-100 (in PBS) for 10 min, washed three times with PBS for 5 min each time; blocked with 3% BSA for 30 min (in PBS), incubated overnight at 4°C with primary antibody (1:50), washed three times with polybutylene terephthalate (PBST) for 5 min each time; incubated at room temperature for 1 h with fluorescent secondary antibody (1:500), washed three times with PBST for 5 min each time; 4',6-diamidinyl-2-phenylindole (DAPI) solution was added, incubated in the dark for 10 min, washed three times with PBST for 5 min each time, the membrane was placed on a glass slide with the cell side facing up, 2 μL of anti-fluorescence quencher was added to each sample, covered with a glass slide, sealed with nail polish, stored in the dark, and 3D images were taken using an upright confocal microscope to observe the polarity expression of OAT1, OAT3, and OCT2 transporters.

[0066] (2) ZO-1 immunofluorescence staining: the method is the same as (1), and the expression of tight junction protein ZO-1 is observed.

[0067] (3) Fluorescein isothiocyanate (FITC)-inulin permeability test: FITC-inulin (0.1 mg / mL) was added to the upper chamber and incubated at 37℃ for 30 min before the fluorescence intensity in the lower chamber was detected.

[0068] (4) Transendothelial resistance (TEER) measurement: Before measurement, place the cells at room temperature for 30 min to equilibrate. Immerse the electrode tip in an electrode solution similar to the culture medium. After zeroing, immerse the short end of the electrode inside the culture plate and the long end outside. The short end should not touch the cells growing on the chamber membrane, and the long end should touch the bottom of the outer well and be at a 90° angle to the culture plate. To ensure the stability and reproducibility of the experimental results, and to ensure the electrode is stable, use the resistance value of the Transwell chamber without seeded cells as a control.

[0069] Figure 2 The polar distribution and barrier function of transport proteins OAT1, OAT3, and OCT2 after HK2-NC and HK2-OAT1-OAT3-OCT2 cells form a dense monolayer on a PET membrane;

[0070] In this diagram, A represents the confocal 3D images of OAT1, OAT3, and OCT2 in HK2-NC and HK2-OAT1-OAT3-OCT2 cells; B represents the expression of tight junction proteins in HK2-NC and HK2-OAT1-OAT3-OCT2 cells; C represents the fluorescence intensity of FITC-inulin permeability; and D represents the transendothelial resistance level.

[0071] Figure 2 As can be seen, after HK2-OAT1-OAT3-OCT2 forms a dense monolayer on the PET membrane, the expression of OAT1, OAT3, and OCT2 transporters is distributed in the upper layer, consistent with the physiological polarity distribution of transporters in the proximal tubules of the human kidney. Tight junction protein ZO-1 is continuously distributed at cell-cell junctions, inulin permeability is <5%, and the TEER value is significantly higher than that of the blank PET membrane (approximately 150 Ω·cm). 2 This indicates that the cells, after forming a dense monolayer, can exhibit a significant polar distribution and possess good barrier function.

[0072] Example 3

[0073] Verification of transporter function of the engineered human renal tubular epithelial cell line HK2-OAT1-OAT3-OCT2 constructed in Example 1.

[0074] After HK2-NC and HK2-OAT1-OAT3-OCT2 cells were plated, the anion transporter substrate furosemide and the competitive inhibitor substrate p-aminohippuric acid, the cation transporter substrate metformin and the competitive inhibitor substrate amantadine were added, respectively. The uptake capacity of the transporters for the fluorescent substrates and the inhibitory effect of the competitive inhibitor substrates on the uptake capacity of the transporters were detected by alkaline lysis method and flow cytometry.

[0075] Alkaline lysis method: HK2-NC and HK2-OAT1-OAT3-OCT2 cells were digested and diluted to 4×10⁻⁶ cells. 5 At a concentration of / mL, 500 μL of suspension was added to each well of a 24-well plate, with 4 replicates per group. After overnight culture, the culture medium was discarded, and the cells were washed twice with PBS. 200 μL of substrate solution prepared with PBS was added to each well, and the cells were incubated at 37°C for 10 min. The supernatant was discarded, and the cells were washed twice with PBS to stop uptake. 200 μL of 0.1M NaOH was added, and the cells were lysed at 37°C for 10 min. 100 μL of supernatant from each well was transferred to a 96-well plate, and fluorescence intensity was measured using a Victor X3 multi-plate reader (FITC excitation 485 nm, emission 535 nm; Cy5 excitation 635 nm, emission 650 nm).

[0076] Flow cytometry: Discard the culture medium, wash twice with PBS, add 200 μL of substrate solution prepared with PBS to each well, incubate at 37°C for 10 min, discard the supernatant, wash twice with PBS to stop uptake, add 200 μL of trypsin to each well, incubate at 37°C for 2 min, add 200 μL of 1640 complete culture medium to stop digestion, mix well by pipetting, transfer to 1.5 mL EP tubes, centrifuge at 1500 rpm for 5 min, discard the supernatant, resuspend in 500 μL of PBS, centrifuge at 1500 rpm for 5 min, discard the supernatant, resuspend in 500 μL of PBS, centrifuge at 1500 rpm for 5 min, discard the supernatant, resuspend in 500 μL of PBS, gently pipette well, filter through a sieve, load the flow cytometry solution, and analyze the results.

[0077] Figure 3 In the table, A and B represent the OAT1 / OAT3 transporter function in HK2-NC and HK2-OAT1-OAT3-OCT2 cells, respectively (alkaline lysis method); C and D represent the OCT2 transporter function in HK2-NC and HK2-OAT1-OAT3-OCT2 cells, respectively (alkaline lysis method); E-H represent the OAT1 / OAT3 transporter function in HK2-NC and HK2-OAT1-OAT3-OCT2 cells, respectively (flow cytometry method); I-L represent the OCT2 transporter function in HK2-NC and HK2-OAT1-OAT3-OCT2 cells, respectively (flow cytometry method).

[0078] Figure 3 The results showed that when engineered HK2 cells were incubated with the specific substrate FITC-furosemide (10 μM) for 10 min, flow cytometry and alkaline lysis fluorescence detection showed a significant increase in the intensity of the fluorescent substrate uptake by the cells. After adding the competitive inhibitory substrate para-aminohippuric acid (PAH, 200 μM), the fluorescence intensity decreased, demonstrating the transport function of OAT1 / OAT3. In the same experiment using the specific substrate Cy5-metformin (10 μM), the intensity of the fluorescent substrate uptake by the cells increased significantly. After adding the competitive inhibitory substrate amantadine (AMA, 200 μM), the uptake was significantly inhibited, demonstrating the transport function of OCT2.

[0079] Example 4

[0080] This embodiment is only an application example of the cell line provided by the present invention. Although the foregoing embodiments have fully demonstrated the advantages of the engineered cell line provided by the present invention, in order to further verify its effect in actual clinical applications, the inventors have conducted the following clinical trials. The following experiments are only for supplementary evidence and should not be used to limit the present invention.

[0081] This embodiment is a specific clinical application of the HK2-OAT1-OAT3-OCT2 cell line constructed in Example 1 in a bioartificial kidney device. The bioartificial kidney device mentioned below can be the structure shown below, or it can be other bioartificial kidney devices in the art that can achieve the same function.

[0082] Figure 4 China A Figure 4 B, Figure 4 C, Figure 4 D, Figure 4 Chinese E, Figure 4 Figures A and F respectively illustrate the structure of the bioartificial kidney device provided by this invention. Figures A and F are exploded views of the overall structure of the bioartificial kidney device. From top to bottom, the components are: dialysate channel 11, sealing and spacer structure 3 (black silicone gasket, the same below), cell support membrane 2 (PET membrane, 0.4μm pore size), sealing and spacer structure 3, blood channel 10, sealing and spacer structure 3, cell support membrane 2, sealing and spacer structure 3, dialysate channel 11. In addition, one end of the blood channel 10 is provided with a blood channel inlet 101, and the other end is provided with a blood channel outlet 102; one end of the dialysate channel 11 is provided with a dialysate channel inlet 111, and the other end is provided with a dialysate channel outlet 112. The dialysate channel 11 and the blood channel 10 of the aforementioned bioartificial kidney device together constitute the outer shell of the bioartificial kidney device. The outer shell is made of polycarbonate (PC) (11.5 cm × 5.7 cm × 1.8 cm in size), and its inner surface is coated with an anticoagulant coating, which is sodium heparin.

[0083] In the figure, B represents the components of the completed bioartificial kidney device, C represents the assembled bioartificial kidney device, D represents the PET membrane, E represents the connection diagram of the bioartificial kidney device during use, and F represents the detailed disassembly and connection structure diagram of the bioartificial kidney device.

[0084] The assembly steps of the above-mentioned bioartificial kidney device are as follows: First, the PET membrane is autoclaved and irradiated with ultraviolet light for 30 min. Then, HK2-OAT1-OAT3-OCT2 cells are added at a rate of 1×10⁻⁶. 6 pcs / cm 2The cells are densely seeded onto a PET membrane and statically cultured in an incubator for 7 days to form a dense monolayer. The PET membrane with cells is then placed in the middle of a PC shell, with silicone gaskets and dialysate channel covers placed on either side in sequence. These are secured with screws to ensure a tight seal. The system connects to the blood inlet, blood outlet, dialysate inlet, and dialysate outlet, and is then connected to a peristaltic pump system. This bioartificial kidney device uses three tubing lines: dialysate channels at the top and bottom, and a blood channel in the middle. Blood flows through the blood chamber and dialysate flows through the dialysate chamber via the yellow tubing of the peristaltic pump, returning to the blood centrifuge tube and dialysate centrifuge tube respectively. This cycle is repeated, and uremic toxins in the blood are taken up and secreted by the dense cell monolayer seeded on the PET membrane.

[0085] In the bioartificial kidney device provided by this invention, a blood input line, a blood output line, and a blood-driven pump together constitute a blood circulation system. The blood input line and the blood output line are respectively connected to the inlet 101 and the outlet 102 of the blood channel 10. In addition, a dialysate input line, a dialysate output line, and a dialysate-driven pump together constitute a dialysate circulation system. The dialysate input line and the dialysate output line are respectively connected to the inlet 111 and the outlet 112 of the dialysate channel 11. The blood circulation system and the dialysate circulation system are integrated with a pressure sensor, a bubble detector, and a temperature controller to monitor operating parameters in real time and ensure treatment safety.

[0086] The working principle of the bioartificial kidney device is as follows:

[0087] The shell has a central blood channel 10 and two dialysate channels 11 located on either side of it. The blood channel 10 and the dialysate channels 11 are separated by a cell support membrane 2 and a sealing and spacer structure 3. During operation, blood from the patient enters the blood channel 10 through the inlet 101 of the blood channel, flows along the blood channel, and returns to the patient's body through the outlet 102 of the blood channel. At the same time, sterile dialysate enters the dialysate channels 11 through the inlet 111 of the dialysate channel and exits through the outlet 112 of the dialysate channel.

[0088] Engineered renal tubular epithelial cells are seeded on cell support membrane 2. After 7 days of static culture, a dense monolayer is formed. Cells form a closed structure through tight junction proteins. The cell support membrane and the dense monolayer formed on its surface together constitute a barrier interface, forming a cellular biomembrane that can effectively isolate the blood channel from the dialysate channel, prevent direct mixing of the two fluids, and provide a structural basis for selective transmembrane transport.

[0089] Furthermore, this cell line can stably overexpress OAT1, OAT3, and OCT2. During culture, these transport proteins exhibit a polar distribution, concentrating on the basal side of the cell (i.e., the side facing the blood), consistent with the physiological polarity of human renal proximal tubular epithelial cells. When blood containing uremic toxins (such as indophenol sulfate, p-cresol sulfate, hippuric acid, creatinine, guanidinosuccinic acid, etc.) flows through blood channel 10, organic anionic toxins are actively taken up from the blood into the engineered renal tubular epithelial cells via OAT1 / OAT3, while organic cationic toxins (such as creatinine) are actively taken up via OCT2. Intracellular toxins are further transported through intracellular pathways and discharged into dialysate channel 11 via the apical side of the cell.

[0090] The inner surface of the shell is coated with an anticoagulant coating (such as heparin coating, phosphorylcholine coating, or albumin coating), which can significantly reduce platelet adhesion and fibrinogen adsorption, thereby reducing the risk of thrombosis.

[0091] 4.1 Verification of in vivo clearance efficiency of the bioartificial kidney device

[0092] Male SD rats, weighing 250–300 g, were used to establish an acute kidney injury model (elevated serum creatinine and blood urea nitrogen) via a single intraperitoneal injection of 6 mg / kg cisplatin. After successful model establishment, the rats were randomly divided into four groups: a model control group (no cell seeding), a treatment group using a bioartificial kidney device, and three groups (n=3 per group) seeded with HK2 cells (normal HK2 cell line without engineered modification).

[0093] The treatment group received a bioartificial kidney device seeded with HK2 cells, HK2-NC cells, or HK2-OAT1-OAT3-OCT2 cells, connected to a rat femoral artery-femoral vein circuit (heparin anticoagulation). Extracorporeal circulation was performed at a flow rate of 1 mL / min for 4 h. The model control group underwent the same procedure, but the bioartificial kidney device was not seeded with cells. After circulation, blood was collected, centrifuged at 3500 rpm for 10 min, and serum was separated. Creatinine and blood urea nitrogen levels were measured using biochemical reagent kits. The results are as follows: Figure 5 As shown.

[0094] Figure 5 In the image, A shows the establishment of blood circulation between the bioartificial kidney device and the femoral artery and vein of the rat; B shows the detection results of creatinine levels in each group of rats; and C shows the detection results of blood urea nitrogen levels in each group of rats.

[0095] The results in the figure show that, compared with the control group, serum creatinine levels in rats decreased after treatment with HK2 cells, HK2-NC cells, and HK2-OAT1-OAT3-OCT2 cells, with the most significant decrease observed in HK2-OAT1-OAT3-OCT2 cells. This may be because creatinine is a substrate of OCT2, and approximately 10%-40% of creatinine secretion by the renal tubules depends on this active transport process. After engineering modification, the OCT2 expression level in HK2 cells in the bioartificial kidney device was significantly increased. Therefore, OCT2 has a stronger active uptake effect on creatinine, and its efficiency in transporting creatinine is significantly improved compared with the unmodified cell group.

[0096] In addition, compared with the control group, there was no significant change in urea nitrogen levels in the HK2 cell group and the HK2-NC cell group, while the urea nitrogen level in the HK2-OAT1-OAT3-OCT2 cell group was significantly reduced.

[0097] Furthermore, during the entire experiment, no thrombosis or air bubbles were formed during the operation of the bioartificial kidney device, and the animal's vital signs remained stable. This demonstrates that the bioartificial kidney device provided by this invention has the potential for long-term continuous blood purification and replacement of kidney physiological functions in clinical applications, and that the device is highly safe and biocompatible.

[0098] 4.2 In vitro clearance experiment of uremic toxins by bioartificial kidney device

[0099] The experiment was divided into four groups: a model control group (without cell seeding), a bioartificial kidney device treatment group (with HK2 cell seeding, HK2-NC cell seeding, and HK2-OAT1-OAT3-OCT2 cell seeding, respectively, n=3 in each group).

[0100] A mixed solution of six uremic toxins—p-cresyl sulfate, indoxyl sulfate, indole-3-acetic acid, hippuric acid, kynurenine, and guanidinosuccinic acid—was prepared. The concentrations of each uremic toxin were screened to ensure they had no effect on cell viability over 24 hours. After the toxin solutions were thoroughly mixed, they were introduced into the bloodstream at a flow rate of 1 mL / min and circulated at 37°C for 4 hours. Blood was collected, and plasma was obtained by centrifugation at 3500 rpm for 10 minutes. Changes in uremic toxin levels were detected by LC-MS.

[0101] Figure 6 China A Figure 6 B, Figure 6 C, Figure 6 D, Figure 6 Chinese E, Figure 6The values ​​F represent the clearance efficiencies of the bioartificial kidney device for cresol sulfate, indophenol sulfate, indole-3-acetic acid, hippuric acid, kynurenic acid, and guanidinosuccinic acid, respectively.

[0102] In the figure, Control group: toxin levels after cell-free BAK circulation;

[0103] HK2 group: Toxin levels in ordinary HK2 cells after BAK circulation;

[0104] HK2-NC group: Toxin levels in control HK2 cells after BAK cycling were overexpressed;

[0105] HK2-OAT1-OAT3-OCT2 group: BAK toxin levels in HK2 cells overexpressing OAT1, OAT3, and OCT2 after circulation.

[0106] The results shown in the figure indicate that HK2-OAT1-OAT3-OCT2 cells exhibited a clearance rate of 43% for cresol sulfate, 84% for indophenol sulfate, 67% for indole-3-acetic acid, 92% for hippuric acid, 74% for kynurenic acid, and 54% for guanidinosuccinic acid. This significantly reduced the levels of these six uremic toxins, with clearance efficiency far superior to that of HK2 and HK2-NC cells. There was no statistically significant difference in clearance efficiency between HK2 and HK2-NC cells for cresol sulfate, indophenol sulfate, and indole-3-acetic acid. HK2 cells showed better clearance efficiency for hippuric acid than HK2-NC cells, but lower clearance efficiency for kynurenic acid and guanidinosuccinic acid.

[0107] Example 5

[0108] The difference between this embodiment and Embodiment 4 is that a polysulfone membrane is used instead of a PET membrane as the cell support membrane.

[0109] A cell carrier layer containing L-Dopa and human type IV collagen was set on the cell side surface of the PSF membrane cell support membrane. The specific operation was as follows: hollow fiber tubes of the PSF membrane were cut into 10 cm lengths and irradiated with UV lamp for 2 h. 2 mg / mL of L-Dopa was dissolved in 10 mM Tris buffer (filtered with a 0.22 μm filter for sterilization). The fiber tubes were completely submerged in the L-Dopa solution and incubated overnight at 37°C. The cells were washed twice with PBS. 25 μg / mL of human type IV collagen was diluted in PBS and the fiber tubes were completely submerged. The cells were incubated at 37°C for 2 h and washed twice with PBS. HK2-OAT1-OAT3-OCT2 cells were then seeded onto the membrane. The cells adhered well in the end.

[0110] The above in vitro and in vivo experiments sufficiently demonstrate that the engineered human renal tubular epithelial cell line provided by this invention can simultaneously overexpress OAT1, OAT3, and OCT2 in HK2 cells, which is expected to more comprehensively restore proximal tubular transport function, expand the range of recognition and uptake of uremic toxins with different chemical properties, and especially enhance the clearance capacity of protein-bound uremic toxins, thereby providing a more feasible cellular basis for the functional reconstruction of bioartificial kidney systems. In addition, the cellularized biomembrane prepared by combining this cell line with PET membrane or PSF membrane can effectively remove creatinine, urea nitrogen, and protein-bound uremic toxins in bioartificial kidney devices, and has good biocompatibility, thus providing a safe and efficient new renal replacement therapy for patients with end-stage renal failure.

[0111] Comparative Example 1

[0112] The only difference from Example 4 is that a PES film is used instead of a PET film, wherein the PES film models are UE010 and UE020 respectively.

[0113] The UE010 and UE020 membranes used in this comparative example are too stiff. When placed in the culture plate, they cannot adhere flatly to the bottom and often bulge. In addition, the membranes are white and opaque, which is not conducive to observation, and the cell adhesion is not ideal.

[0114] Comparative Example 2

[0115] The only difference from Example 1 is that only OAT1 and OAT3 are overexpressed.

[0116] Comparative Example 3

[0117] The only difference from Example 1 is that only OCT2 is overexpressed.

[0118] Comparative Example 4

[0119] The only difference from Example 1 is that only OAT1 and OCT2 are overexpressed.

[0120] The engineered cell lines obtained in Comparative Examples 2-4 were used to make bioartificial kidney devices according to the method in Example 4, and their effects were verified. The experimental results showed that when the engineered cell lines overexpressed only one or two of OAT1, OAT3, and OCT2, the efficiency of uremic toxin clearance decreased significantly, and the extent of the decrease depended on the type of target toxin and whether there was still "uptake-efflux" synergy. Overall, when all three are overexpressed simultaneously, engineered renal tubular epithelial cells exhibit broader coverage of toxins of different types. This is because OAT1 and OAT3 are primarily responsible for the uptake of organic anionic uremic toxins, especially for the clearance of protein-bound anionic toxins, while OCT2 is mainly responsible for the transport of organic cationic toxins. When only one is retained, the clearance capacity is significantly narrowed, usually only enhancing the transmembrane transport of a certain type of toxin, while having limited effect on other types of toxins: that is, overexpressing only OAT1 and OAT3 can maintain a strong clearance capacity for anionic toxins, but the treatment of cationic toxins will be significantly insufficient; conversely, overexpressing only OCT2 can improve the clearance of cationic toxins to some extent, but the improvement is limited for most protein-bound anionic uremic toxins, which are of greater clinical concern; overexpressing only OAT1 or only OAT3 will further limit the effect, because the substrate profiles of the two partially overlap but are not completely the same, and enhancing only one often only covers a portion of the toxins.

[0121] The above are merely preferred embodiments of the present invention and do not limit the scope of the patent. All equivalent changes and modifications made within the scope of the present invention should still fall within the scope of the present invention.

Claims

1. An engineered human renal tubular epithelial cell line, characterized in that, Named HK2-OAT1-OAT3-OCT2, it was deposited on September 1, 2026, at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, with accession number CGMCC No. 46875.

2. The engineered human renal tubular epithelial cell line as described in claim 1, characterized in that, The cell line is the HK2 human renal tubular epithelial cell line, which overexpresses organic anion transporter OAT1, organic anion transporter OAT3, and organic cation transporter OCT2.

3. The method for constructing an engineered human renal tubular epithelial cell line as described in claim 1, characterized in that, The steps include the following: Acquisition and artificial synthesis of the S1 target gene sequence The gene sequences of human OAT1, OAT3, and OCT2 were obtained from the NCBI gene database, and the target genes of OAT1, OAT3, and OCT2 were artificially synthesized. Construction of S2 recombinant expression vector The target genes OAT1, OAT3, and OCT2 synthesized in S1 were cloned into the PiggyBac vector carrying the TET-On inducible gene expression regulation system and GFP fluorescent label, and a recombinant PiggyBac plasmid carrying the OAT1, OAT3, and OCT2 genes was constructed. The nucleotide sequence is shown in SEQ ID NO:

1. S3 plasmid transfection The recombinant PiggyBac plasmid of S2 was transfected into the human renal tubular epithelial cell line HK2 to obtain a human renal tubular epithelial cell line that stably overexpresses OAT1, OAT3, and OCT2.

4. A cellularized biomembrane, characterized in that, Includes the engineered human renal tubular epithelial cell line as described in any one of claims 1-3 and a cell support membrane, wherein the engineered human renal tubular epithelial cell line is seeded onto the cell support membrane; The cell support membrane is selected from any one of PET membrane, PES-50 membrane, silicon nanoporous membrane, PES / PVP composite membrane, and polysulfone membrane.

5. The cellularized biomembrane as described in claim 4, characterized in that, The cell support membrane is a PET membrane.

6. The cellularized biomembrane as described in claim 4, characterized in that, The cell-side membrane surface of the cell support membrane is provided with a cell carrier layer, wherein the cell carrier layer is selected from at least one of the following: A surface-modified layer, which is formed by at least one of plasma treatment, collagen coating, laminin modification, or fibronectin modification. A hydrogel layer, wherein the material of the hydrogel layer is selected from at least one of gelatin, alginate, Matrigel matrix gum or collagen; The nanofiber scaffold layer is prepared by electrospinning, and its material is selected from at least one of polycaprolactone, polylactic acid-glycolic acid copolymer or gelatin.

7. The cellularized biomembrane as described in claim 6, characterized in that, The cell support membrane is a polysulfone membrane.

8. The cellularized biomembrane as described in claim 4, characterized in that, The non-cellular side surface of the cell support membrane is further provided with at least one layer of porous alumina immune isolation membrane.

9. The use of the engineered human renal tubular epithelial cell line according to any one of claims 1-3 in the preparation of cell models for drug development and nephrotoxicity testing.

10. The use of the engineered human renal tubular epithelial cell line according to any one of claims 1-3 or the cellularized biomembrane according to any one of claims 4-9 in the preparation of products for treating end-stage renal failure or for removing uremic toxins.

Citation Information

Patent Citations

  • Human normal kidney immortalized cell line NRC-X1 and application thereof

    CN120866232A